Diabetic nephropathy: Aldosterone breakthrough in patients on an ACEI

Nature Reviews Nephrology

Volumn 6, Issue 4, 2010, Pages 194-196

  Nakagawa, Takahiko ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN; PLACEBO; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN;

ALBUMINURIA; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG EFFICACY; HUMAN; KIDNEY FUNCTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; TREATMENT OUTCOME;

ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETIC NEPHROPATHIES; HUMANS;

EID: 77950252859     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2010.32     Document Type: Short Survey

References (10)

1. Mehdi, U. F., Adams-Huet, B., Raskin, P., vega, G. L. & Toto, R. D. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 20, 2641-2650 (2009).
2. Brenner, B. M. et al. effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
3. suissa, s., Hutchinson, T., Brophy, J. M. & Kezouh, A. ACe-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int. 69, 913-919 (2006).
4. Mauer, M. et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. 361, 40-51 (2009).
5. Mann, J. F. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the OnTARGeT study): a multicentre, randomised, double-blind, controlled trial. Lancet 372, 547-553 (2008).
6. Perkins, B. A., Ficociello, L. H., Roshan, B., warram, J. H. & Krolewski, A. s. in patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int. 77, 57-64 (2010).
7. Kosugi, T., Heinig, M., nakayama, T., Matsuo, s. & nakagawa, T. enOs knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists. Am. J. Pathol. 176, 619-629 (2010).
8. Hanke, C. J. & Campbell, w. B. endothelial cell nitric oxide inhibits aldosterone synthesis in zona glomerulosa cells: modulation by oxygen. Am. J. Physiol. Endocrinol. Metab. 279, e846-e854 (2000).
9. Arima, s. et al. endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 43, 352-357 (2004).
10. ikeda, H. et al. spironolactone suppresses inflammation and prevents L-nAMe-induced renal injury in rats. Kidney Int. 75, 147-155 (2009).